Abstract
The combination of irinotecan (daily for 5 days for 2 consecutive weeks) and ifosfamide (daily on days 1 through 3) was investigated in children with osteosarcoma. Irinotecan pharmacokinetic investigations were performed before ifosfamide (day 1), after 3 days of ifosfamide (day 3), and 9 days after the end of ifosfamide (day 12). On day 3, the concentrations of irinotecan's active metabolite, SN-38, were below the limit of quantitation in two patients and were decreased in a third patient. The SN-38 area under the concentration-time curve remained below the day 1 value in two patients on day 12. The reduced area under the curve to the active metabolite SN-38 during ifosfamide therapy predicts a compromised efficacy of irinotecan in this combination.
Original language | English (US) |
---|---|
Pages (from-to) | 764-767 |
Number of pages | 4 |
Journal | Journal of Pediatric Hematology/Oncology |
Volume | 26 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2004 |
Externally published | Yes |
Keywords
- Ifosfamide
- Irinotecan
- Osteosarcoma
- Pediatrics
- Solid tumor
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology